Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

Clinical trial NCT01423058 · COMPLETED

Trial details

NCT number: NCT01423058
Sponsor: Sierra Oncology LLC - a GSK company
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Primary Myelofibrosis Post-Polycythemia Vera Post-Essential Thrombocythemia Myelofibrosis

Start date: 2011-08-01
Primary completion: 2014-06-01
Enrollment: 61

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.